-
摘要: 目的观察和对比拉米夫定单用与联合苦参素、胸腺肽治疗慢性乙型肝炎的临床疗效及安全性。方法将162例慢性乙型肝炎患者分为联合组与单用组。联合组87例,应用拉米夫定与苦参素、胸腺肽联合治疗;单用组75例,采用拉米夫定单药治疗。疗程均为12月,随访12月。观察两组中HBeAg、HBeAg/HBeAb血清转换、HBVDNA的阴转情况,同时观察肝功能变化。结果联合组显效32例(36.8%),有效41例(47.1%),无效14例(16.1%),总有效率83.9%;单用组显效8例(10.7%),有效34例(45.3%),无效33例(44%),总有效率56%,两组有效率对比差异有统计学意义P<0.01。联合组YMDD突变率明显低于单用组。结论拉米夫定联合苦参素、胸腺肽治疗慢性乙型肝炎疗效明显优于单用拉米夫定。
-
[1]Lai CL, Dienstag J, Schiff E, et al.Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B[J].Clin Infect Dis, 2003, 36:687-696. [2]中华医学会.病毒性肝炎防治方案[J].中华传染病杂志, 2001, 19 (1) :56. [3] 中华医学会.慢性乙型肝炎防治指南[J].中华肝脏病杂志, 2005, 13 (12) :881-891. [4]姚光弼, 王宝恩, 崔振宇, 等.拉米夫定治疗慢性乙型肝炎病人的长期疗效[J].中华肝脏病杂志, 1999, 7 (2) :80-83. [5]Allen ML, Deslauriers M, Andrews C W, et al.Identification and characterization of mutations in hepatitis B virus resistant to lamivudi-ne[J].Hepatology, 1998.1670-1677. [6]Rolukbas C, Bolukbas FF, Kendir T, et al.The effectiveness of lami-vudine treatment in cirrhotic patients with HBV precore mutations:a prospective, open-label study[J].Dig Dis Sci2006, 51:1196-1202. [7]Wang ZY, Zhang DZ, Ren H, et al.Investigation of entecavir medica-tion of chronic B patients in the Chongqong area who failed lami-vu-dine treatment[J].Zhonghua Ganzanghing Zazhi, 2007, 1:14-15. [8]Chisari F.Immunology of viral hepatitis B.In Post-graduate course2000, up-date viral hepatitis[J].AASLD Postgraduate Course, 2000, 7 (2) :92-94. [9]符静, 陈良.拉米夫定联合胸腺肽治疗慢性乙型肝炎的疗效[J].中华传染病杂志, 2003, 21:287. [10]张玲, 马韵, 黄绍标, 等.苦参素注射液治疗慢性乙型肝炎的组织病理学分析[J].中华肝脏病杂志, 2003, 11 (1) :45. [11]王俊学, 王国俊.苦参碱及氧化参碱的药理作用及临床应用[J].肝脏, 2000, 6 (5) :116-117.
本文二维码
计量
- 文章访问数: 1946
- HTML全文浏览量: 5
- PDF下载量: 743
- 被引次数: 0